Sun Pharma, Dr Reddy’s, Max Healthcare: Pharma, hospital stocks in focus amid reports of 30% anti-cancer drug margin cap

Shares of pharma and hospital stocks such as Sun Pharmaceutical Industries and Dr Reddy’s Laboratories, along with hospital operators Max Healthcare Institute, Fortis Healthcare, Apollo Hospitals and Global Health (Medanta) are expected to be in the limelight on Friday, October 9.

According to news agency PTI, the proposed measure will cover 110 medicines, including 35 patented drugs, and is expected to be implemented later this month.

While the move aims to make cancer treatment more affordable, its impact on individual pharma companies and hospital chains will depend on their exposure to the affected medicines and the role they play in their distribution and sale.

What is a trade margin?

It is the difference between the price at which a drug is supplied to a distributor or retailer and the price at which it is sold to the patient, expressed under the applicable pricing framework.

What you need to know

The decision, according to reports and analysts, is potentially negative for pharmaceutical companies that sell high-priced anti-cancer drugs with large trade margins, but positive for patients because it aims to reduce treatment costs.

The impact on individual pharma stocks will depend on how much of their revenue comes from the affected medicines and how much margin they currently earn through the distribution chain.